Clinical Trial

Fibrinogen-to-Albumin Ratio as a Predictor of Acute Respiratory Distress Syndrome in Traumatic Brain Injury

Study acronym: FARDS
Recruiting
View on ClinicalTrials.gov →
Summary
this study aims to assess the ability of fibrinogen-to-albumin ratio to predict the development of Acute respiratory distress syndrome in traumatic brain injury patients.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-07-07
notable Primary completion moved earlier: 2026-12-01 -> 2026-10-01 2026-07-07
Trial Details
NCT Number NCT07664358
Lead Sponsor Tanta University
Conditions Fibrinogen, Albumin, ARDS, TBI (Traumatic Brain Injury)
Enrollment 350 participants
Start Date 2026-07-01
Primary Completion 2026-10-01 (estimated)
Study Completion 2027-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-06